What Ghana’s Vaccine Ambitions Teach Us About Africa’s Health Sovereignty

Category

Health Innovation Festival

Country

Ghana

Pillar

Health Entrepreneurship

Tag

Health Entrepreneurship

The opening ceremony of the Africa Health Collaborative’s flagship Health Innovation Festival (HIFest) 2026, held on June 4, 2026, at the Fiesta Royale Hotel, Accra, was energetic and inspiring. Innovators, researchers, entrepreneurs, investors, and ecosystem leaders from across Africa and Canada gathered to explore how locally driven innovation can shape more resilient and self-sustaining health systems.

In his keynote address, Dr. Sodzi Sodzi-Tettey, CEO of Ghana’s National Vaccine Institute (NVI), outlined a compelling vision for continental health sovereignty. He emphasized that true independence requires African nations to strengthen their local research, manufacturing, and innovation ecosystems. Highlighting Ghana’s progress, Dr. Sodzi-Tettey shared how the country is building a resilient, self-sufficient vaccine manufacturing capacity—not only to protect its own citizens but also to contribute significantly to global health security.

The Vision of Health Sovereignty 

Africa’s brilliant minds and dedicated policymakers are working tirelessly to secure healthy futures for their communities. Yet, some significant systemic barriers persist. Currently, Africa manufactures less than 1% of the vaccines it uses, leaving many countries heavily dependent on external supply chains. Recent global health crises, such as COVID-19, have demonstrated that relying heavily on external supply chains forces African nations to wait while other regions address their own national needs first.

Dr. Sodzi-Tettey emphasized ‘the next global health crisis is a matter of when, not if‘. His call to action: Africa must continue building the capacity to develop, manufacture, and deliver health solutions that are responsive to its own priorities and realities.

Ghana’s Strategic Blueprint and Achievements

Dr. Sodzi-Tettey presented Ghana’s efforts as a leading example of this shift toward greater health self-reliance. As the country prepares to graduate from Gavi, the Vaccine Alliance program by 2030, it is not merely adapting to a funding shift; it is transforming its healthcare system by manufacturing its own vaccines. The establishment of the National Vaccine Institute represents a definitive step toward strengthening domestic capacity for vaccine research, development, and manufacturing.

This strategic drive extends beyond traditional vaccines. Local innovators and scientists are already pioneering the local manufacture of critical, region-specific medical supplies, such as snake venom antiserum, antitetanus serum and tetanus diphtheria vaccine. This local R&D in Ghana is ensuring that the country’s healthcare solutions are intrinsically suited and immediately available to its people.

Overcoming Market Barriers Through Partnership

Vaccines exist within a tightly controlled global market where long-term purchasing commitments from governments are critical. As Dr. Sodzi-Tettey noted, individual national markets—including Ghana’s—are often too small to independently sustain large-scale, cost-effective vaccine manufacturing.

The solution to this hurdle lies in a unified, Pan-African market access strategy. To overcome limitations in scale, Ghana is leveraging public funds to procure its own locally produced vaccines while aggressively expanding its market reach through three key pillars:

Continental Aggregation: Leveraging the Africa CDC’s Africa Pooled Procurement mechanism, which aggregates demand across the continent and enables Ghana to supply vaccines to peer African nations.

Regional Expansion: Targeting the ECOWAS market of approximately 400 million people.

Bilateral Agreements: Partnering with countries graduating from the Gavi program to secure buyers as vaccines become available.

This is where true, equitable partnership comes into play. A prime example is Ghana’s technology transfer agreement with Indonesia’s PT Biopharma, which is currently collaborating with Atlantic Lifesciences in Ghana to manufacture the country’s first vaccine. Beyond production, this partnership is actively driving regulatory capacity building, ensuring that Ghana-made vaccines meet the highest global standards and compliance frameworks.

Catalytic investments in research, manufacturing, and innovation ecosystems will be essential to advancing Africa’s health sovereignty. But financial capital is just one piece of the puzzle. Addressing these barriers will require coordinated action from governments, investors, regulators, universities, and ecosystem partners working together to create enabling environments for innovation.

The Way Forward

The solutions Africa needs will emerge when bright minds come together with a shared commitment. Through initiatives such as HIFest and its broader Health Entrepreneurship portfolio, the Africa Health Collaborative supports young innovators to test ideas, build partnerships, access mentorship, and strengthen pathways for scaling health solutions across the continent.

Africa’s path to health will depend on sustained investment in local innovation, stronger regional collaboration, and continued support for homegrown research and manufacturing capacity. Together, governments, universities, investors, innovators, and development partners can help build a more resilient, self-sufficient, and equitable healthcare future for Africa.

Watch the full address